ESTRO 2025 - Abstract Book

S4157

RTT - Patient experience and quality of life

ESTRO 2025

completed two questionnaires Patient Reported Outcomes (PROMs): the EORTC QLQ_C30 and the EORTC_ELD_14 quality of life (QoLs), baseline, at the end of the RT and 3 months later.

Results: A total of 156 patients with a mean age of 77 years (range 70-93) were included. The characteristics of the patients and the results of the baseline PROMs are shown in Table 1. The baseline general health status of patients >70 years shows some deterioration (73.5 ± 20.3). Patients also present deterioration in physical function (85.29 ± 19.94), emotional function (81.02 ± 21.28) and maintenance of purpose (70.94 ± 30.5) and the most frequent baseline symptoms are: constipation, fatigue, insomnia, worries about others, future worries, disease burden and joint stiffness. The prognostic factors that increase the risk of these alterations are: ECOG >1, sex = female, diabetes, dyslipidemia, pulmonary pathology, cognitive impairment and especially the risk of sarcopenia. When comparing PROMs at the beginning and at the end of oncological treatment, a significant deterioration in role function (89.86 vs 85.62, p = 0.004) and an increase in fatigue (19.89 vs 25.78, p = 0.002) are observed. While the PROMs at 3 months show improvement in all functions and symptoms, although statistically significant improvement was only found in emotional function (84 vs 89.26, p = 0.000), fatigue (25.87 vs 20.4, p = 0.001), loss of appetite (12.75 vs 6.7, p = 0.003) and maintenance of purpose (68 vs 73.6, p = 0.14). Figure 1.